Floatz logo

(+)-VINCRISTINE

Head and Neck Squamous Cell Carcinoma

Neonc Technologies, Inc.Small moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
65/ 100

Competitive context

129 Active assets in the Head and Neck Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Epirubicin
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Cetuximab
Fate Therapeutics
Phase 3B
Docetaxel
National Cancer Institute (NCI)
Phase 3B

View all 50 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →